

Remarks/Arguments:

Applicants have added new Claim 26 which claims *N*-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1*H*-pyrazol-5-yl)acetamide or a pharmaceutically acceptable salt thereof. Support for this claim can be found on page 31, lines 3-4 and on page 120, lines 2-3 of the specification.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

The Commissioner is hereby authorized to charge for excess claim fees. Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100938-1P US.

Respectfully submitted,
/Theresa Devlin/

Name: Theresa Devlin
Dated: 15 February 2008
Reg. No.: 45,361
Phone No.: 781-839-4969
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451